A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.

Adam Sharp; Anja Williams; Sarah Blagden; Elizabeth Plummer; Daniel Hochhauser; Matthew Krebs; Simon Pacey; Jeff Evans; Sarah Whelan; Srinand Nandakumar; Seema Rogers; Katherine Jameson; Frank Basile; Johann Bono; Hendrik-Tobias Arkenau

doi:10.1200/JCO.2022.40.16_suppl.TPS2691

A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.

Adam Sharp, Anja Williams, Sarah Blagden, Elizabeth Plummer, Daniel Hochhauser, Matthew Krebs, Simon Pacey, Jeff Evans, Sarah Whelan, Srinand Nandakumar, Seema Rogers, Katherine Jameson, Frank Basile, Johann Bono, Hendrik-Tobias Arkenau

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	TPS2691-TPS2691
Journal	Journal of Clinical Oncology
Volume	40
DOIs	https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2691
Publication status	Published - 1 Jun 2022

Access to Document

10.1200/JCO.2022.40.16_suppl.TPS2691

Cite this

Sharp, A., Williams, A., Blagden, S., Plummer, E., Hochhauser, D., Krebs, M., Pacey, S., Evans, J., Whelan, S., Nandakumar, S., Rogers, S., Jameson, K., Basile, F., Bono, J., & Arkenau, H.-T. (2022). A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology, 40, TPS2691-TPS2691. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2691

@article{275eb1f936234ff7ac0045a47192e412,

title = "A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.",

author = "Adam Sharp and Anja Williams and Sarah Blagden and Elizabeth Plummer and Daniel Hochhauser and Matthew Krebs and Simon Pacey and Jeff Evans and Sarah Whelan and Srinand Nandakumar and Seema Rogers and Katherine Jameson and Frank Basile and Johann Bono and Hendrik-Tobias Arkenau",

year = "2022",

month = jun,

day = "1",

doi = "10.1200/JCO.2022.40.16_suppl.TPS2691",

language = "English",

volume = "40",

pages = "TPS2691--TPS2691",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Sharp, A, Williams, A, Blagden, S, Plummer, E, Hochhauser, D, Krebs, M, Pacey, S, Evans, J, Whelan, S, Nandakumar, S, Rogers, S, Jameson, K, Basile, F, Bono, J & Arkenau, H-T 2022, 'A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.', Journal of Clinical Oncology, vol. 40, pp. TPS2691-TPS2691. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2691

TY - JOUR

T1 - A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.

AU - Sharp, Adam

AU - Williams, Anja

AU - Blagden, Sarah

AU - Plummer, Elizabeth

AU - Hochhauser, Daniel

AU - Krebs, Matthew

AU - Pacey, Simon

AU - Evans, Jeff

AU - Whelan, Sarah

AU - Nandakumar, Srinand

AU - Rogers, Seema

AU - Jameson, Katherine

AU - Basile, Frank

AU - Bono, Johann

AU - Arkenau, Hendrik-Tobias

PY - 2022/6/1

Y1 - 2022/6/1

U2 - 10.1200/JCO.2022.40.16_suppl.TPS2691

DO - 10.1200/JCO.2022.40.16_suppl.TPS2691

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

SP - TPS2691-TPS2691

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -